SECTIONS
SUBSCRIBE
Managed Care

Search form

  • News
  • Politics & policy
  • Drug management
  • Payers
  • Providers
  • Current Issue
  • More
    • Past issues
    • Value-Based Care
    • Profiles
    • Conversations
    • Tomorrow's Medicine
    • Original research
    • Pharm D Corner
    • Viewpoints
    • Legislation & regulation
    • Contact Us

Most Popular

Growing Number in High-Deductible Plans

For Americans younger than 65, the share of people with private health insurance in a high-deductible plan increased from 39.4% in 2016 to 42.9% in 2017.

Read more

Infant Mortality Varies by State

The overall infant mortality rate in the U.S. declined 14% between 2005 and 2015, from 6.86 infant deaths per 1,000 live births in 2005 to 5.90 in 2015, according to the CDC. However, CDC researchers found wide variation among the states, ranging from 9.08 deaths per 1,000 live births in Mississippi (the highest rate), to 4.28 deaths per 1,000 live births in Massachusetts (the lowest).

Read more

Long wait time to see an ob/gyn

Women who were new patients waited an average of nearly 24 days to be seen by an ob/gyn, according to research by Athenahealth. In contrast, the new-patient wait to see for an orthopedist was 13 days. Waits for first appointments with primary care physicians, pediatricians, and cardiologists fell in between those two extremes.

Read more

What Women’s Health Wants in Your Market

Women are a key focus segment for health care organizations both because of the medical services they utilize as individuals and the influence they have on the health care of others. In one survey, 59% of women and 94% of working moms reported making or heavily influencing health care decisions for their entire families.

Read more

FDA OKs Three Merck/Pfizer Drugs for Type-2 Diabetes

The FDA has approved three new drugs for type-2 diabetes: Steglatro tablets (ertugliflozin), an oral sodium-glucose cotransporter 2 (SGLT2) inhibitor; Steglujan tablets (ertugliflozin/sitagliptin), the only fixed-dose combination of an SGLT2 inhibitor and the dipeptidyl peptidase-4 inhibitor sitagliptin;…
Read more

François de Brantes axed by Altarum

François de Brantes, whose payment reform organization merged with the Altarum institute about a year ago, has been fired. His last day was Friday. An email from Altarum’s president and CEO, Lincoln Smith, that circulated at the institute, said he had “tremendous respect” for de Brantes but after…
Read more

Boomers, Millennials Hit Hard by Opioids

Baby boomers and millennials are the hardest hit by the heroin and opioid epidemic. Boomers, born between 1946 and 1964, top the list, having 27% greater chance of dying from prescription opioids than people born in 1977 and 1979, the baseline group. They also have a 33% chance of dying from a heroin overdose.

Read more

Deep Brain Stimulation Presents Radical Fix to Dire Opioid Crisis

Cut an inch-long incision into someone’s scalp. Then drill a hole into the skull that’s no bigger than a dime. Insert an electrode directly into the brain that targets the reward center, the nucleus accumbens. Then thread a wire beneath the skin to a pacemaker implanted in the patient’s chest. That’s deep brain stimulation.

Read more

Earlier Diabetes Increases Mortality

Two men are the same age and they’ve both been diagnosed with type 2 diabetes. One was diagnosed 10 years before the other, though. The man with the earlier onset of type 2 diabetes has about a 30% to 60% greater risk of dying from any cause.

Read more

Finding Our Way To Serving the Underserved

It’s a must because there is a cost to keeping the underserved that way whether that means funding integrated primary care to help people live healthier lives or footing the bill when people get care in the emergency department.

Read more

Why Medicaid Managed Care Is Looking Outside the Traditional Coverage Box

Social factors, like access to healthy food, stable housing, a steady income, and reliable transportation, may have more to do with a sick person getting well than anything that a health plan, doctor, or hospital can do. That’s been well documented by numerous studies and the likes of the World Health…
Read more

How RWE Is Becoming the Real Deal

The randomized controlled trial reigns supreme, but the FDA is working on ways to incorporate real-world evidence into its approval processes.

Read more

FDA Grants Breakthrough Therapy Designation to Balovaptan for Autism

The FDA has awarded a breakthrough therapy designation to the investigational oral drug balovaptan (previously known as RG7314, Roche), a vasopressin 1a (V1a) receptor antagonist for individuals with autism spectrum disorder (ASD). Balovaptan has shown the potential to improve social interaction and…
Read more

Heated Chemotherapy “Bath” Improves Ovarian Cancer Survival

In women with metastatic ovarian cancer restricted to the abdominal cavity (stage III), hyperthermic intraperitoneal chemotherapy (HIPEC) improves survival with almost no additional side effects, according to research published in the New England Journal of Medicine. The research, led by the Netherlands…
Read more

Take a Bow, Pharma, for the Hepatitis C Drugs

The direct-acting virals revolutionized the treatment of hepatitis C. They also ushered turbocharged pricing. At least patients—and society—got a major health benefit in return.

Read more

Pages

  • « first
  • ‹ previous
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • …
  • next ›
  • last »
Facebook Twitter LinkedIn RSS Feed
  • Contact Us
  • Our History
  • Terms & Conditions of Use Agreement
  • Address and Subscription Changes
  • 2018 Editorial Calendar
  • 2018 Space and Material Due Dates
  • BPA Statement
  • Submitting Original Research
  • Submitting Viewpoints
  • Site Map
  • Contact Webmaster
  • P&T Community
© 2018 MediMedia, an ICON plc company. All rights reserved.